UK Markets closed

L'Oréal S.A. (OR.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
354.80+7.30 (+2.10%)
At close: 05:35PM CET
Full screen
Previous close347.50
Open349.00
Bid0.00 x 0
Ask0.00 x 0
Day's range347.60 - 356.05
52-week range300.45 - 433.65
Volume654,038
Avg. volume403,098
Market cap197.862B
Beta (5Y monthly)0.60
PE ratio (TTM)55.96
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.80 (1.49%)
Ex-dividend date27 Apr 2022
1y target estN/A
  • Reuters

    L'Oréal denies report saying it suspended Twitter ad spending

    "L'Oréal did not make any decision to suspend advertising spending on Twitter," a company spokesperson told Reuters in an email. Twitter did not immediately respond to Reuters' requests for comment. Last week, top U.S. automaker General Motors Co said it had temporarily halted paid advertising on Twitter after Elon Musk completed his takeover of the social media company.

  • Motley Fool

    Is Now the Right Time to Buy L'Oréal Stock?

    L'Oréal (ENXT: OR) (OTC: LRLCY) might seem like a great stock to buy as inflation, rising interest rates, and other macro headwinds rattle the broader markets. The French cosmetics giant -- which also owns Lancôme, Maybelline, NYX Cosmetics, and Garnier -- mainly targets higher-income consumers who are better insulated from those economic shockwaves.

  • Reuters

    L'Oreal's hair straighteners caused woman's cancer, lawsuit claims

    L'Oreal SA has been sued by a Missouri woman who alleges she developed uterine cancer as a result of using the French cosmetic company's hair-straightening products. The lawsuit, filed Friday in federal court in Chicago, came days after a study from the U.S. National Institute of Environmental Health Safety (NIEHS) finding that hair-straightening products may significantly increase the risk of uterine cancer among frequent users. The plaintiff, Jennifer Mitchell, said she was diagnosed with uterine cancer in 2018, after using L'Oreal's products since about 2000, when she was 10.